Foundations laid for further growth
In October 2019, Impax reported impressive AUM growth, closing FY19 on £15.1bn, up 21% on FY18 (AUM...
Read moreFull-year results
Oxford Biodynamics’ EpiSwitch platform has won widespread recognition this year, including a fifth...
Read moreOn track to hit FY20 expectations
Success in business, investing and life in general revolves around seizing opportunities, whilst...
Read moreOn the road towards mainstream adoption
Occasionally on the FTSE, there can be such a wide disconnect between price & value that it is...
Read moreEncouragement from interims
ReNeuron Group plc is an AIM listed biotechnology company developing allogeneic cell therapies. Its...
Read moreGrowth outlook remains sweet
Cake Box, which announced strong interim results today, benefits from a unique value for money...
Read moreNow the dust has settled
ReNeuron Group is an AIM listed biotechnology company developing allogeneic cell therapies. Their...
Read moreGrowth, profitability, opportunity
Tatton, the UK's largest provider of on-platform discretionary fund management services to IFAs,...
Read more
Offering the best of both worlds
Watkin Jones is a rare breed. Not only is this developer & manager of large scale, multi occupancy...
Read moreBumper £81m payday coming soon
Like it or not, but we're on the verge of a golden era of technological innovation, thanks to rapid...
Read moreScale-up train on track
Tatton's trading statement for the half-year ending 30 September 2019 confirmed continued momentum...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
